Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors

Alsina, 2003, Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma, Clinical Cancer Research, 9, 6419 Amaria, 2018, Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: A single-centre, open-label, randomised, phase 2 trial, The Lancet Oncology, 19, 181, 10.1016/S1470-2045(18)30015-9 Ascierto, 2015, What's new in melanoma? Combination!, Journal of Translational Medicine, 13, 213, 10.1186/s12967-015-0582-1 Ascierto, 2016, Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial, The Lancet Oncology, 17, 1248, 10.1016/S1470-2045(16)30122-X Banks, 2017, Cardiovascular effects of the MEK inhibitor, Trametinib: A case report, literature review, and consideration of mechanism, Cardiovascular Toxicology, 17, 487, 10.1007/s12012-017-9425-z Bronte, 2015, What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment, Oncotarget, 6, 35589, 10.18632/oncotarget.5853 Bronte, 2015, Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy, Expert Opinion on Drug Safety, 14, 253, 10.1517/14740338.2015.986092 Cardinale, 2015, Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy, Circulation, 131, 1981, 10.1161/CIRCULATIONAHA.114.013777 Cartlidge, 2008, Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival, Pigment Cell & Melanoma Research, 21, 534, 10.1111/j.1755-148X.2008.00491.x Collisson, 2003, Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade, Cancer Research, 63, 5669 Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 Di Lisi, 2017, Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond, International Journal of Cardiology, 227, 11, 10.1016/j.ijcard.2016.11.174 Dossett, 2015, BRAF and MEK inhibition in melanoma, Expert Opinion on Drug Safety, 14, 559, 10.1517/14740338.2015.1011618 Dummer, 2018, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial, The Lancet Oncology, 19, 603, 10.1016/S1470-2045(18)30142-6 Flaherty, 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations, The New England Journal of Medicine, 367, 1694, 10.1056/NEJMoa1210093 Flaherty, 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma, The New England Journal of Medicine, 367, 107, 10.1056/NEJMoa1203421 Grohé, 1998, Expression of oestrogen receptor alpha and beta in rat heart: Role of local oestrogen synthesis, The Journal of Endocrinology, 156, R1, 10.1677/joe.0.156R001 Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial, Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X Hausenloy, 2009, Cardioprotective growth factors, Cardiovascular Research, 83, 179, 10.1093/cvr/cvp062 Iijima, 2002, c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells, The Journal of Biological Chemistry, 277, 23065, 10.1074/jbc.M200328200 Isenberg, 2008, CD47: A new target in cardiovascular therapy, Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 615, 10.1161/ATVBAHA.107.158154 Kabir, 2015, G protein-coupled estrogen receptor 1 mediates acute estrogen-induced cardioprotection via MEK/ERK/GSK-3β pathway after ischemia/reperfusion, PLoS One, 10, 10.1371/journal.pone.0135988 Kaplan, 2011, Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells, Oncogene, 30, 366, 10.1038/onc.2010.408 Khan, 2018, RAS-mediated oncogenic signaling pathways in human malignancies, Seminars in Cancer Biology, 10.1016/j.semcancer.2018.03.001 Koo, 2002, Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase, Proceedings of the National Academy of Sciences of the United States of America, 99, 3052, 10.1073/pnas.052707699 Kramann, 2014, B-RAF and its novel negative regulator reticulocalbin 1 (RCN1) modulates cardiomyocyte hypertrophy, Cardiovascular Research, 102, 88, 10.1093/cvr/cvu024 Kubin, 2017, The MEK1 inhibitors UO126 and PD98059 block PDGF-AB induced phosphorylation of threonine 292 in porcine smooth muscle cells, Cytokine, 95, 51, 10.1016/j.cyto.2017.02.003 Kubin, 2011, Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling, Cell Stem Cell, 9, 420, 10.1016/j.stem.2011.08.013 Lahtinen, 1991, Cardiotoxicity of epirubicin and doxorubicin: A double-blind randomized study, European Journal of Haematology, 46, 301, 10.1111/j.1600-0609.1991.tb01543.x Larkin, 2014, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, The New England Journal of Medicine, 371, 1867, 10.1056/NEJMoa1408868 Li, 2016, Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells, Cancer Letters, 370, 332, 10.1016/j.canlet.2015.11.015 Lips, 2004, MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo, Circulation, 109, 1938, 10.1161/01.CIR.0000127126.73759.23 Liu, 2017, BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma, Oncotarget, 8, 69477, 10.18632/oncotarget.17704 Long, 2017, Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma, The New England Journal of Medicine, 377, 1813, 10.1056/NEJMoa1708539 Long, 2014, Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, The New England Journal of Medicine, 371, 1877, 10.1056/NEJMoa1406037 Long, 2015, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial, Lancet, 386, 444, 10.1016/S0140-6736(15)60898-4 McArthur, 2014, Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study, The Lancet Oncology, 15, 323, 10.1016/S1470-2045(14)70012-9 Naitoh, 2006, MitoKATP channel activation suppresses gap junction permeability in the ischemic myocardium by an ERK-dependent mechanism, Cardiovascular Research, 70, 374, 10.1016/j.cardiores.2006.01.023 Node, 1997, Amelioration of ischemia- and reperfusion-induced myocardial injury by 17beta-estradiol: Role of nitric oxide and calcium-activated potassium channels, Circulation, 96, 1953, 10.1161/01.CIR.96.6.1953 Planchard, 2016, Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial, The Lancet Oncology, 17, 984, 10.1016/S1470-2045(16)30146-2 Planchard, 2017, Dabrafenib plus trametinib in patients with previously untreated BRAF, The Lancet Oncology, 18, 1307, 10.1016/S1470-2045(17)30679-4 Queirolo, 2015, Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma, Cancer Treatment Reviews, 41, 519, 10.1016/j.ctrv.2015.04.010 Robert, 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib, The New England Journal of Medicine, 372, 30, 10.1056/NEJMoa1412690 Rose, 2010, Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale, Physiological Reviews, 90, 1507, 10.1152/physrev.00054.2009 Sumimoto, 2006, The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells, The Journal of Experimental Medicine, 203, 1651, 10.1084/jem.20051848 Zachary, 2001, Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor, American Journal of Physiology. Cell Physiology, 280, C1375, 10.1152/ajpcell.2001.280.6.C1375 Zhu, 2017, Increased apoptosis in the paraventricular nucleus mediated by AT1R/Ras/ERK1/2 signaling results in sympathetic hyperactivity and Renovascular hypertension in rats after kidney injury, Frontiers in Physiology, 8, 41, 10.3389/fphys.2017.00041